Inherited thrombophilic abnormalities and risk of portal vein thrombosis: A meta-analysis

Thrombosis and Haemostasis

Volumn 99, Issue 4, 2008, Pages 675-682

  Dentali, Francesco ^a   Galli, Matteo ^a   Gianni, Monica ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Hepatology; Thrombophilia; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ARTICLE; CALCULATION; COCHRANE LIBRARY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; EMBASE; HUMAN; MEDICAL EXPERT; MEDLINE; MODEL; MUTATION; OUTCOME ASSESSMENT; POPULATION; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICS; THROMBOPHILIA; WESTERN EUROPE;

EUROPE; FACTOR V; FEMALE; HUMANS; MALE; ODDS RATIO; POINT MUTATION; PORTAL VEIN; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 43749103164     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-08-0526     Document Type: Article

References (51)

1. Balfour GW, Stewart TG. Cases of enlarged spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of the portal vein. Edimburrg Med J 1869; 14: 589-598.
2. Okuda K, Ohnishi K, Kimura K, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89: 279-286.
3. Sarfeh IJ. Portal vein thrombosis associated with cirrhosis: clinical importance. Arch Surg 1979; 114: 902-905.
4. Gayowski TJ, Marino IR, Doyle HR, et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996; 60: 333-338.
5. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
6. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
7. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
8. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
9. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
10. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
11. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
12. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
13. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-816.
14. Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
15. McGinn T, Wyer PC, Newman TB, et al for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004; 171: 1369-1373.
16. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-2012.
17. Hayden GF, Kramer MS, Horwitz RI. The case-control study. A practical review for the clinician. J Am Med Assoc 1982; 247: 326-331.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
21. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323: 101-105.
22. Mahmoud AEA, Elias E, Beauchamp N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800.
23. Chamouard P, Pencreach E, Maloisel F, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116: 144-148.
24. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-348.
25. Egesel T, Buyukasik Y, Dundar SV, et al. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000; 30: 66-71.
26. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
27. Gomez MR. Garcia ES. Lacomba DL, et al. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000; 31: 237-240.
28. Janssen HLA, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study. Blood 2000; 96: 2364-2368.
29. Amitrano L, Brancaccio V, Guardascione MA, et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol 2001; 96: 146-149.
30. Madonna P, De Stefano V, Coppola A, et al. G20210A prothrombin gene mutation and other trombophilic polymorphisms in patients with portal or hepatic venous thrombosis. Gastroenterology 2001; 120: 1059-1060.
31. Janssen HLA. Role of coagulation in the natural history and treatment of portal vein thrombosis. J Gastroenterol Hepatol 2001; 16: 595-596.
32. De Stefano V, Teofili L, Leone G, et al. Acquired and inherited risk factors for splanchnic venous thrombosis. Blood 2001; 97: 3314-3315.
33. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70: 126-132.
34. Amitrano L, Brancaccio V, Guardascione MA, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: Role of genetic thrombophilia. Endoscopy 2002; 34: 535-538.
35. Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002; 71: 89-93.
36. Elefsiniotis IS, Diamantis ID, Dourakis SP, et al. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis. Eur J Gastroenterol Hepatol 2003; 15: 721-726.
37. Oksuzoglu G, Bayraktar Y, Arslan S, et al. Portal vein thrombosis in cirrhotics: Related with anticardiolipin antibodies? Hepato-Gastroenterology 2003; 50: 1527-1530.
38. Barcellona D, Fenu L, Cauli C, et al. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemost 2003; 90: 1061-1064.
39. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741.
40. Samonakis DN, Koutroubakis IE, Sfiridaki A, et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 2004; 49: 854-858.
41. Erkan O, Bozdayi AM, Disibeyaz S, et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-343.
42. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41: 603-608.
43. Fernandez-Miranda C, Coto A, Martinez J, et al. Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677CT mutation in venous thromboembolism risk of young adults. Medicina Clinica 2005; 124: 532-534.
44. Mangia A, Villani MR, Cappucci G, et al. Causes of portal venous thrombosis in cirrhotic patients: The role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17: 745-751.
45. Matsutani S, Maruyama H, Akiike T, et al. Study of portal vein thrombosis in patients with idiopathic portal hypertension in Japan. Liver International 2005; 25: 978-983.
46. Maakaroun A, Delahousse B, Fimbel B, et al. G20210A prothrombin gene mutation appears as the most important inherited prothrombotic risk factor in 'idiopathic' portal vein thrombosis. ISTH Congress abstract. J Thromb Haemost 2003; 1: Abstract P0335.
47. Macarone Palmieri N, Tufano A, Coppola A, et al. Genetic and acquired risk factors in patients with portal and mesenteric venous thrombosis. ISTH Congress abstract. J Thromb Haemost 2005; 3: Abstract P2326.
48. Amitrano L, Guardascione MA, Ames PR, et al A. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb Haemost 2006; 95: 221-223.
49. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 2000; 32: 865-871.
50. Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979; 48: 627-639.
51. Robson SC, Kahn D, Kruskal J, et al. Disordered hemostasis in extrahepatic portal hypertension. Hepatology 1993; 18: 853-857.